123 related articles for article (PubMed ID: 12492108)
1. Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.
Glaser KB; Li J; Aakre ME; Morgan DW; Sheppard G; Stewart KD; Pollock J; Lee P; O'Connor CZ; Anderson SN; Mussatto DJ; Wegner CW; Moses HL
Mol Cancer Ther; 2002 Aug; 1(10):759-68. PubMed ID: 12492108
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors.
Feng XH; Filvaroff EH; Derynck R
J Biol Chem; 1995 Oct; 270(41):24237-45. PubMed ID: 7592630
[TBL] [Abstract][Full Text] [Related]
4. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.
Abe M; Harpel JG; Metz CN; Nunes I; Loskutoff DJ; Rifkin DB
Anal Biochem; 1994 Feb; 216(2):276-84. PubMed ID: 8179182
[TBL] [Abstract][Full Text] [Related]
5. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Elbendary A; Berchuck A; Davis P; Havrilesky L; Bast RC; Iglehart JD; Marks JR
Cell Growth Differ; 1994 Dec; 5(12):1301-7. PubMed ID: 7696178
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Sowa Y; Orita T; Minamikawa S; Nakano K; Mizuno T; Nomura H; Sakai T
Biochem Biophys Res Commun; 1997 Dec; 241(1):142-50. PubMed ID: 9405248
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of G1 phase cyclin dependent kinases by transforming growth factor beta 1.
Reddy KB; Hocevar BA; Howe PH
J Cell Biochem; 1994 Nov; 56(3):418-25. PubMed ID: 7876335
[TBL] [Abstract][Full Text] [Related]
9. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
Han JW; Ahn SH; Park SH; Wang SY; Bae GU; Seo DW; Kwon HK; Hong S; Lee HY; Lee YW; Lee HW
Cancer Res; 2000 Nov; 60(21):6068-74. PubMed ID: 11085529
[TBL] [Abstract][Full Text] [Related]
10. Quantification of transforming growth factor-beta in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct.
van Waarde MA; van Assen AJ; Kampinga HH; Konings AW; Vujaskovic Z
Anal Biochem; 1997 Apr; 247(1):45-51. PubMed ID: 9126369
[TBL] [Abstract][Full Text] [Related]
11. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest.
Claassen GF; Hann SR
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9498-503. PubMed ID: 10920185
[TBL] [Abstract][Full Text] [Related]
12. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells.
Xiao H; Hasegawa T; Isobe K
J Cell Biochem; 1999 Jun; 73(3):291-302. PubMed ID: 10321829
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta down-regulation of CKShs1 transcripts in growth-inhibited epithelial cells.
Simon KE; Cha HH; Firestone GL
Cell Growth Differ; 1995 Oct; 6(10):1261-9. PubMed ID: 8845303
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21waf1 induction are important early events.
Malliri A; Yeudall WA; Nikolic M; Crouch DH; Parkinson EK; Ozanne B
Cell Growth Differ; 1996 Oct; 7(10):1291-304. PubMed ID: 8891333
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: the Abbott experience.
Curtin M; Glaser K
Curr Med Chem; 2003 Nov; 10(22):2373-92. PubMed ID: 14529480
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
[TBL] [Abstract][Full Text] [Related]
18. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.
Myzak MC; Karplus PA; Chung FL; Dashwood RH
Cancer Res; 2004 Aug; 64(16):5767-74. PubMed ID: 15313918
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression.
Young DA; Billingham O; Sampieri CL; Edwards DR; Clark IM
FEBS J; 2005 Apr; 272(8):1912-26. PubMed ID: 15819885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
